Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp

Nature

Volumn 514, Issue 7520, 2014, Pages 47-53

  Qiu, Xiangguo ^a   Wong, Gary ^a,b   Audet, Jonathan ^a,b   Bello, Alexander ^a,b   Fernando, Lisa ^a   Alimonti, Judie B ^a   Fausther Bovendo, Hugues ^a,b   Wei, Haiyan ^a,c   Aviles, Jenna ^a   Hiatt, Ernie ^d   Johnson, Ashley ^d   Morton, Josh ^d   Swope, Kelsi ^d   Bohorov, Ognian ^e   Bohorova, Natasha ^e   Goodman, Charles ^e   Kim, Do ^e   Pauly, Michael H ^e   Velasco, Jesus ^e   Pettitt, James ^f,h   Olinger, Gene G ^f,h   Whaley, Kevin ^e   Xu, Bianli ^c   Strong, James E ^a,b   Zeitlin, Larry ^e   Kobinger, Gary P ^a,b,g   more..

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d Kentucky BioProcessing ^*  (United States)

^e Mapp Biopharmaceutical Inc   (United States)

^f UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; CREATININE; GLUCOSE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ZMAPP1; MONOCLONAL ANTIBODY ZMAPP2; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; ENVELOPE GLYCOPROTEIN, EBOLA VIRUS; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIBODY; BIOASSAY; DISEASE TREATMENT; ENZYME; OPTIMIZATION; POPULATION OUTBREAK; PRIMATE; SPATIOTEMPORAL ANALYSIS; SYMPTOM; VACCINATION; VIRAL DISEASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE SEVERITY; DRUG BINDING; DRUG CROSS REACTIVITY; DRUG MIXTURE; EBOLA HEMORRHAGIC FEVER; ENZYME LINKED IMMUNOSORBENT ASSAY; EPISTAXIS; FEMALE; FEVER; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; INTERVENTION STUDY; LEUKOCYTOSIS; LEUKOPENIA; MALE; MUCOSAL BLEEDING; NICOTIANA BENTHAMIANA; NONHUMAN; PETECHIA; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RASH; RHESUS MONKEY; SURVIVAL RATE; THROMBOCYTOPENIA; UREA NITROGEN BLOOD LEVEL; VIREMIA; VIRUS SHEDDING; WEIGHT REDUCTION; AMINO ACID SEQUENCE; ANIMAL; BLOOD; CHEMISTRY; CROSS REACTION; EBOLA VIRUS; GUINEA; GUINEA PIG; IMMUNOLOGY; MOLECULAR GENETICS; PASSIVE IMMUNIZATION; SEQUENCE ALIGNMENT; VIROLOGY;

WEST AFRICA;

ANIMALIA; EBOLA VIRUS; MACACA MULATTA; PRIMATES;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS REACTIONS; EBOLAVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GUINEA; GUINEA PIGS; HEMORRHAGIC FEVER, EBOLA; IMMUNIZATION, PASSIVE; MACACA MULATTA; MALE; MOLECULAR SEQUENCE DATA; SEQUENCE ALIGNMENT; VIRAL ENVELOPE PROTEINS; VIREMIA;

EID: 84907263545     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature13777     Document Type: Article

References (30)

1. Bausch, D. G., Sprecher, A. G., Jeffs, B. & Boumandouki, P. Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions. Antiviral Res. 78, 150-161 (2008).
2. Baize, S. et al. Emergence of Zaire Ebola virus disease in Guinea - preliminary report. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1404505 (2014).
3. WHO. Ebola virus disease (EVD) http://www.who.int/csr/don/archive/disease/ebola/en/ (accessed, 15 August 2014).
4. CDC. Chronology of Ebola Hemorrhagic Fever Outbreaks, http://www.cdc.gov/vhf/ebola/resources/outbreak-table.html (accessed, 15 August 2014).
5. Reliefweb. W. African Ebola epidemic 'likely to last months': UN http://reliefweb.int/report/guinea/w-african-ebola-epidemic-likely-last-months-un (7 March 2014).
6. Clark, D. V., Jahrling, P. B. & Lawler, J. V. Clinical management of filovirus-infected patients. Viruses 4, 1668-1686 (2012).
7. Guimard, Y. et al. Organization of patient care during the Ebola hemorrhagic fever epidemic in Kikwit, Democratic Republic of the Congo, 1995. J. Infect. Dis. 179 (Suppl. 1), S268-S273 (1999).
8. Hensley, L. E. et al. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J. Infect. Dis. 196 (Suppl 2), S390-S399 (2007).
9. Geisbert, T. W. et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 362, 1953-1958 (2003).
10. Geisbert, T. W. et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375, 1896-1905 (2010).
11. Warren, T. K. et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nature Med. 16, 991-994 (2010).
12. Feldmann, H. et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog. 3, e2 (2007).
13. Olinger, G. G., Jr et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc. Natl Acad. Sci. USA 109, 18030-18035 (2012).
14. Qiu, X. et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci. Transl. Med. 4, 138ra181 (2012).
15. Pettitt, J. et al. Therapeutic intervention of Ebola virus infectionin rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci. Transl. Med. 5, 199ra113 (2013).
16. Qiu, X. et al. mAbs and Ad-vectored IFN-α therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Sci. Transl. Med. 5, 207ra143 (2013).
17. Giritch, A. et al. Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. Proc. Natl Acad. Sci. USA 103, 14701-14706 (2006).
18. Jahrling, P. B. et al. Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J. Infect. Dis. 179 (Suppl 1), S224-S234 (1999).
19. Qiu, X. et al. EbolaGP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS Negl. Trop. Dis. 6, e1575 (2012).
20. Wilson, J. A. et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287, 1664-1666 (2000).
21. Qiu, X. et al. Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin. Immunol. 141, 218-227 (2011).
22. Dye, J. M. et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc. Natl Acad. Sci. USA 109, 5034-5039 (2012).
23. Wong, G. et al. Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci. Transl. Med. 4, 158ra146 (2012).
24. Marzi, A. et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc. Natl Acad. Sci. USA 110, 1893-1898 (2013).
25. ProMEDmail.org. Ebola virus disease - West Africa (117): WHO, Nigeria, Liberia, drug, more. http://www.promedmail.org/direct.php?id52666073 (6 August 2014).
26. NC3RS. Practical blood sample volumes for laboratory animals, domestic species and non-human primates. http://www.nc3rs.org.uk/bloodsamplingmicrosite/page.asp?id5426 (accessed, 3 August 2014).
27. Qiu, X. et al. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci. Rep. 3, 3365 (2013).
28. Wong, G. et al. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine http://dx.doi.org/10.1016/j.vaccine.2014.08.028 (in the press).
29. Mupapa, K. et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J. Infect. Dis. 179 (Suppl. 1), S18-S23 (1999).
30. UPMChealthsecurity.org. Next-Generation Monoclonal Antibodies: Challenges and Opportunities http://www.upmchealthsecurity.org/our-work/pubs-archive/pubs-pdfs/2013/2013-02-04-next-gen-monoclonal-antibodies.pdf (UPMC Center for Biosecurity, 2013).